Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:734 |
Name | urethra cancer |
Definition | An urinary tract cancer that derives_from the tissues of the urethra. |
Source | DiseaseOntology.org |
Alt Ids | DOID:737 |
Path | disease disease of cellular proliferation cancer organ system cancer urinary system cancer urethra cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00942331 | Phase III | Bevacizumab + Cisplatin + Gemcitabine Cisplatin + Gemcitabine | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer | Completed | USA | 1 |
NCT01366144 | Phase I | Paclitaxel Veliparib Carboplatin | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | Active, not recruiting | USA | 0 |
NCT01688999 | Phase II | Cabozantinib | Cabozantinib for Advanced Urothelial Cancer | Completed | USA | 0 |
NCT03023319 | Phase I | Bosutinib + Pemetrexed Disodium | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | Completed | USA | 0 |
NCT03171025 | Phase II | Nivolumab | Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT) | Active, not recruiting | USA | 0 |
NCT03430895 | Phase II | Durvalumab + Tremelimumab | Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract | Completed | USA | 0 |
NCT03582475 | Phase I | Etoposide Carboplatin + Docetaxel + Etoposide + Pembrolizumab Cisplatin + Etoposide + Pembrolizumab Pembrolizumab Carboplatin + Etoposide + Pembrolizumab | Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate | Active, not recruiting | USA | 0 |
NCT05756569 | Phase II | Enfortumab vedotin-ejfv + Pembrolizumab | Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology | Recruiting | USA | 0 |
NCT06638931 | Phase II | Nivolumab | Agnostic Therapy in Rare Solid Tumors (ANTARES) | Recruiting | BRA | 0 |